pharmaphorum August 21, 2024
A study has found a higher risk of suicidal thoughts in users of Novo Nordisk’s GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there was no evidence for a link.
The observational study published in JAMA Network Open used the World Health Organization (WHO) global database of suspected adverse drug reactions, called VigiBase, to look at signals for suicidal and self-harm thinking among users of Novo Nordisk’s semaglutide and liraglutide products up to the end of August last year.
The authors found “significant disproportionality” with semaglutide, the active ingredient in Novo Nordisk’s diabetes drug Ozempic and Wegovy for obesity, but not for liraglutide or other commonly prescribed diabetes drugs, and concluded this...
Today's Sponsors
Today's Sponsor